Skip to main content
Delfa

← All assets

troriluzole

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

0

Recruiting

0

Completed

1

Sites

44

Countries

1

Endpoints

17

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 17 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1

Trials by status

Completed
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
9
Function / daily living
2
Behavior / neuropsychiatric
2
Neuroimaging
2
Safety / tolerability / PK
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 13 of 17 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

4

ADAS-CogCognition

3

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Neuropsychiatric Inventory (NPI)Behavior

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
T2 Protect ADStudy of BHV-4157 in Alzheimer's Disease

troriluzole

Alzheimer’s disease

Alzheimer's diseasePh 2Completed44Dec 20201results

Showing 1-1 of 1 trials